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Abstract: Hypertension (HTN) is a complex disease with interactions among multiple organ systems,
including the heart, vasculature, and kidney with a strong heritable component. Despite the
multifactorial nature of HTN, no clinical guidelines utilize a multi-gene approach to guide blood
pressure (BP) therapy. Non-smokers with a family history of HTN were included in the analysis
(n = 384; age = 61.0 ± 0.9, 11% non-white). A total of 17 functional genotypes were weighted
according to the previous effect size in the literature and entered into an algorithm. Pharmacotherapy
was ranked from 1–4 as most to least likely to respond based on the algorithmic assessment of
individual patient’s genotypes. Three-years of data were assessed at six-month intervals for BP
and medication history. There was no difference in BP at diagnosis between groups matching
the top drug recommendation using the multi-gene weighted algorithm (n = 92) vs. those who
did not match (n = 292). However, from diagnosis to nadir, patients who matched the primary
recommendation had a significantly greater drop in BP when compared to patients who did not.
Further, the difference between diagnosis to current 1-year average BP was lower in the group that
matched the top recommendation. These data suggest an association between a weighted multi-gene
algorithm on the BP response to pharmacotherapy.
Keywords: hypertension; blood pressure; genetics; pharmacogenetics; pharmacotherapy; treatment
1. Introduction
Hypertension (HTN) is a major preventable contributor to cardiovascular disease (CVD) and
accounts for approximately 360,000 of the 2.4 million (14%) annual deaths in the United States [1–3].
High blood pressure represents an estimated $51 billion in direct costs to the United States health
care system [4]. Furthermore, HTN is known to lead to myocardial infarction, stroke, renal failure,
and death if not detected early and treated appropriately, resulting in an estimated $113 billion total
(direct and indirect) annual cost [1,5]. With the advent of improved diagnostic techniques, increased
rates of health care utilization and screening, and the increasing age of the population, a continual
upward trend in this expenditure is expected [6]. Despite the prevalence of HTN, control rates are
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generally poor [7,8]. While 70% of HTN patients are treated, only half of those achieve blood pressure
(BP) control (BP < 140/90 mmHg) [9]. These poor control rates, despite high treatment rates, suggest
that the efficacy of BP therapy goes beyond adherence. This is further supported by detailed studies
that have demonstrated an average effective rate of 50% for each common class of BP medication
(diuretic, ACE-inhibitors, angiotensin-II receptor blockers, beta-blockers) [10], even when adherence
is confirmed. Additionally, most HTN pharmacotherapies demonstrate a bell-curve response, such
that a majority of patients have a reduction or no change in BP, but 10–20% of patients demonstrate an
increase in BP [11,12].
Hypertension has a strong heritable component, estimated at approximately 50%, with current
studies suggesting the responsiveness to HTN therapy may be heritable as well [12–16]. It has
been shown that the risk of developing HTN is increased two-fold for each first degree relative
with HTN [13]. Furthermore, when compared to sons of normotensive individuals, sons of HTN
patients have a 10 mmHg higher systolic and diastolic BP, independent of dietary Na+ intake [13,17].
Additionally, the correlation for risk of HTN development is 55% in monozygous twin siblings, up to
40% in dizygous twins, and as low as 20% for non-twin sibling pairs [18–20]. Collectively, these data
demonstrate a clear genetic component to HTN development. While both genome-wide association
studies and candidate gene studies have demonstrated that HTN monotherapy effectiveness may
be improved using genetics to guide therapy [14,15], few studies have sought to identify the impact
of genotypes, important in BP regulation and pharmacotherapy response, on multiple drug classes
simultaneously [11,15].
In an effort to control HTN, given the potential for ineffective monotherapy, the current standard
of care is to “layer” BP drugs (i.e., increasing dosage to the maximally tolerated dosage then adding a
second HTN therapy on top of the first therapy). If guideline-directed blood pressure goals continue to
be elusive (following layering of several classes of drugs at the maximally-tolerated doses), the process
is reinitiated with a different combination of drugs, different classes of drugs, different drug options
within a given class of drugs, different dosages or all of the above. This trial-and-error standard of care
is clearly not optimal and presents consequences, such as increased side effects, costs to the patient,
increased health care service utilization, and reduced quality of life [21,22]. Furthermore, previous
work has demonstrated an 80% reduction in medication adherence for each new drug prescribed [23].
Research examining genetic determinants to HTN therapy response have identified β1-adrenergic
receptor (ADRB1), β2-adrenergic receptor (ADRB2), cytochrome P450 2D6 (CYP2D6), lysine deficient
protein kinase (WNK), sodium-chloride symporter (SLC12A3), alpha subunit of the epithelial sodium
channel (SCNN1A), alpha-adducin (ADD1), renin, angiotensin, angiotensin-converting enzyme
(ACE), and angiotensin receptor variants as playing key functional roles in response to HTN
therapy [12,16,24–26]. Genetically guided monotherapies based on these functional variants result in
an approximate 4–10 mmHg greater drop in mean arterial pressure (MAP) [12,25–36]. Furthermore,
genotype association studies have demonstrated improved clinical outcomes when the functional
genotype is taken into consideration [11,12,16,24]. These clinical outcomes include: improved K+
and Cl− excretion, decreased adverse events (myocardial infarction, stroke, coronary heart disease)
and decreased mortality risk [37–41]. Despite the clear promise of genetically-guided therapy for BP
control, clinical care settings are slow to adopt this approach.
Collectively, these previous studies demonstrate that genetic variations in proteins responsible
for BP modulation may be responsible, in part, for the variability of HTN therapy effectiveness. To
date, most research on BP therapies efficacy has been monogenic and have not adequately taken into
account the multi-organ and multi-system integrative nature of HTN. Furthermore, while emerging
data has employed the use of a simple algorithm, taking into account the total number of functional
genotypes within an organ system, to predict BP response to therapy, pilot work by our group
has demonstrated that this approach alone does not accurately predict BP response. Indeed, some
genotypes demonstrated functionality with respect to BP response to HTN therapy whereas some
genotypes demonstrated functionality with respect to BP control using a <140/<90 mmHg cutoff. These
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differences suggest that a more complex and logical algorithm is needed to more accurately predict BP
response to HTN therapy [42]. This lack of efficacy when genotypes are considered in isolation is likely
due to the numerous genes that need to be considered to guide therapy, simultaneously and with
gene-gene interactions, and the pathways in the cardiorenal axis responsible for BP control [16,43,44].
In order for HTN pharmacogenetics to be effective, these genes must be weighted based on their effect
size and importance in BP regulation, in order to adequately predict BP response. Therefore, in the
present study, we assessed 17 genotypes within the heart, vasculature, and kidney on the BP response
to therapy. This builds on previous research through the weighting of each genotype by their effect
size (∆BP with treatment for a functional variant on target therapy vs. ∆BP for a non-functional variant
on the same therapy) as determined by previous literature [24,45–60]. After weighting, each genotype
was entered into an algorithm that assessed pairing (e.g., homozygosity of functional ADRB1 allele
is responsive to β-blockade, heterozygosity is less responsive, and homozygosity of non-functional
allele is least responsive) within and between organ systems to predict the pharmacotherapy with the
greatest impact for each individual patient.
2. Methods
2.1. Study Design
This study was designed and performed in a primarily retrospective manner and included patients
within Fairview Health Services (clinicaltrials.gov identifier: NCT02524873). Patients provided DNA
for genetic analysis, and a detailed medical chart review was performed between 30 November 2015
and 30 November 2018 with a focus on the present study in the 12-months prior to DNA collection.
All patients provided written informed consent prior to enrollment and data collection (University
of Minnesota IRB# 00000756). Patients included non-smokers with a family history of HTN and a
history of BP control (<140/<90 for two consecutive office measures). The primary outcome variables
included an office BP (averaged from one year of patient visits) and level of BP control using traditional
guidelines for patients with and without diabetes (<140/<90) and Systolic Blood Pressure Intervention
Trial (SPRINT) guidelines (<120/<80). Primary chart measurements included systolic blood pressure
(SBP) and diastolic blood pressure (DBP), and mean arterial pressure (MAP) was calculated. Additional
measures included current medications, a detailed hypertension medication history, side effects from
previous medications, and medication adherence. Three-years of medical chart data were examined at
six-month intervals for BP and medication history to quantify the number of medications needed to
obtain BP control and BP control history. Current and past pharmacotherapies were also assessed via
chart review. Additional variables included a change in BP measurements from diagnosis to the most
recent one-year chart review period.
2.2. Subjects
All patients enrolled in the study were HTN patients who had their BP under control for at least
six months and who had an HTN diagnosis for at least one year. In addition to BP history, demographic
information collected included age, sex, height, weight, race, and ethnicity. Inclusion criteria for the
study included: 20–85 years of age, patient on the same class/classes of blood pressure medication
for a minimum of six months (a change in dosage, frequency or specific medication was accepted
as long as there had been no changes to the class/classes of medications prescribed), a body mass
index (BMI) between 19 and 45 kg/m2, patient prescribed and taking one of the following classes
of medications alone or in combination: diuretics (thiazide or thiazide-like), ACE inhibitors (ACEI),
angiotensin receptor blocker (ARB), beta-blockers, and Ca2+ channel blockers. Subjects were excluded
from participation if one or more of the following conditions were met: a diagnosis of secondary HTN
or a complication of pregnancy, currently prescribed and taking any additional class of medication(s)
for HTN not included in the inclusion criteria list, and SBP > 140 or DBP > 90 documented within the
immediate six months prior to the study visit.
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2.3. Cell Collection and Genotyping
Two buccal swabs were collected for each patient. Cells were first collected via a buccal brush
by swabbing the inside of their right cheek repeatedly (for fifteen seconds using moderate pressure)
(A-swab). The patient then deposited the swab in 750 µL of lysis buffer consisting of 50 mM Tris
pH 8.0, 50 mM EDTA, 25 mM Sucrose, 100 mM NaCl, and 1% SDS to lyse the cells and stabilize
DNA during transit prior to extraction. This process was repeated with the left cheek (B-swab) to
ensure adequate cell collection necessary to achieve a minimum yield of 500 ng total gDNA for
downstream genotyping. Subsequent lysate from buccal swabs was used in DNA isolation via Qiagen
DNeasy isolation kits according to the manufacturer’s recommended specifications (Qiagen, Hilden,
NorthRhine-Westphalia, Germany). Patient isolated DNA was then assayed for 17 functional alleles in
11 genes with known functionality in the heart, kidney, and vasculature: (1) ADRB1 (rs1801252 and
rs1801253), (2) ADRB2 (rs1042713 and rs1042714), SCNN1A (rs2228576), alpha-adducin (ADD1, rs4961),
SLC12A3 (rs1529927), (3) angiotensin (AGT, rs699, rs5051, and rs7079), renin (REN, rs12750834), WNK1
(rs1159744, rs2107614, and rs2277869), angiotensin-converting enzyme (ACE, rs1799752), angiotensin
receptor (AGTR1, rs5186), and cytochrome P450 2D6 (CYP2D6*4, rs3892097). With the exception of
the ACE insertion/deletion (indel) genotype, all genotype polymorphisms were quantified using a
two-step process beginning with a multiplex PCR, directly followed by a single base extension (SBE)
reaction. The products of the SBE reaction were pooled and subsequently flown on a genomic mass
spectrometer (Agena MassARRAY system, San Diego, CA, USA) to generate individual genotypes.
The ACE indel status was assessed using a standard fluorescently labeled PCR primer set and protocol,
followed by fragment analysis via a 3730 DNA analyzer (Applied Biosystem, Foster City, CA, USA).
Pre-characterized Coriell cell line DNAs consisting of all possible genotype combinations were run in
parallel for each single nucleotide polymorphism (SNP) as controls. All genotype data in aggregate
was also used to compute population allele frequencies which were then confirmed against known
existing frequencies in publically available databases (ExAC browser, 1000 Genomes project, GO-exome
sequencing project, and TOPMED).
2.4. Mathematical Prediction of Drug Responsiveness
This study builds on our previous work in that we use weighted scoring for each genotype to
develop a weighted multi-gene algorithm to determine if a patient would respond to one drug over
another. Functional genotypes affecting BP response to pharmacotherapy as identified by current
literature were included in the mathematical prediction, including 17 SNPs in 11 genes (ADRB1, ADRB2,
CYP2D6, WNK, SLC12A3, SCNN1A, alpha-adducin, renin, angiotensin, ACE, and the angiotensin
receptor). These genotypes were weighted according to previous effect size in the literature (∆BP when
on the target therapy vs. not for functional and non-functional genotypes) as well as the number and
quality of peer-reviewed papers supporting each functional variant. Specifically, the genotypes that
had the largest effect (plasma drug levels or ∆BP with treatment in the functional genotype group vs.
without treatment) were CYP2D6, both sites of ADRB1, position 27 ADRB2, one site of WNK (rs227869),
the alpha-adducin genotype, and two genotypes for angiotensin (rs5051 and rs699) (Table 1). Following
this, the genotypes that seem to had a lower to moderate effect (∆BP in the previous literature) based
on aggregate data included position 27 of the ADRB2, two sites for WNK (rs1159744 and rs2107614),
SLC12A3, SCNN1A, renin, ACE, angiotensin (rs7079), and the angiotensin-II receptor. In addition
to weighing based on the ∆BP from the previous literature, genotypes were also weighted based
on the strength of the peer-reviewed literature. Genotypes with more peer-reviewed papers were
given a higher scoring priority with the assumption that there is more agreement in the functionality,
as also summarized in Table 1. After weighting, each genotype was entered into an algorithm that
assessed pairing (e.g., homozygosity of functional ADRB1 is responsive to β-blockade, heterozygosity
is less responsive, and homozygosity of non-functional is least responsive) within and between organ
systems to predict the pharmacotherapy with the greatest impact for each individual patient. Each
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pharmacotherapy predicted to be beneficial was ranked from 1–4 as most to least likely to be effective
for that patient based on the algorithmic assessment of individual patient’s genotypes.
Table 1. Functional Allele Variants Within Organ Systems, PharmGKB Clinical Annotation Level, and
the Average Mean Arterial Blood Pressure Difference Between Functional and Non-Functional Allele
Variants Used to Build the Mathematical Algorithm.
Target
Organ Gene Allele
Average MAP
Difference between
Functional and
Non-Functional
Number of
Publications
(PubMed)
Key
References
Cardiac
Cyp2D6 *4 rs3892097 0 mmHg 353 * [24,45–60]
ADRB1 49 rs1801252 5.2 mmHg 2749 * [48–50]
ADRB1 389 rs1801253 8.7 mmHg [49–51,61]
ADRB2 16 rs1042713 3.7 mmHg 3067 * [45,62]
ADRB2 27 rs1042714 7 mmHg (SBP only) [63,64]
Vascular
ACE (I/D) rs1799752 4.7 mmHg 1377 [54,65,66]
AGT
rs699 8.3 mmHg 2797 * [54,67]
rs5051 8 mmHg [54,67–70]
rs7079 4.3 mmHg [70,71]
AGTR1 rs5186 3.3 mmHg 1451 [72–76]
REN rs12750834 3.7 mmHg 1085 [30,58]
Renal
SCNN1A rs2228576 N/A 31 [59]
WNK1 (a) rs1159744 3.7 mmHg 35 * [24]
WNK1 (b) rs2107614 5.0 mmHg [24]
WNK1 (c) rs2277869 7.0 mmHg [24]
SLC12A3 rs1529927 N/A 103 [39]
ADD1 rs4961 10 mmHg 52 [40,60,77]
* Inclusive of the functional sites of that gene. MAP: mean arterial blood pressure; SBP: systolic blood pressure.
2.5. Data Analysis
All data were coded for statistical analysis (i.e., drug classes and genotypes coded numerically
according to functionality) and were analyzed with SPSS version 21. Normality of the data was assessed
using Levene’s test prior to statistical analysis to assess equality of variance to ensure appropriate
statistical methodology. Descriptive statistics were computed (age, height, weight, BMI, etc.) and
reported as mean ± standard deviation (SD). Post-hoc correction for univariate analysis of the variance
was conducted using Bonferroni analysis. Ordinary least squares regression via univariate modeling
was used to estimate the magnitude of linearity between drug classes that yielded the best blood
pressure control and those which were mathematically predicted based on the sum of genotypes for
the subject. All statistical analyses were considered significant at an alpha level of 0.05.
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3. Results
Three hundred and eighty-four subjects met the inclusion criteria, were genotyped, and had
complete chart data for review. The distribution of patients currently on the target drug class of each
polymorphism is presented in Table 2. Patients were grouped into those who were on the current
prescription for drug therapy which matched to the top recommendation provided from the algorithm
vs. those who did not match (Table 3). There were no differences in patient age, smoking status,
drinking status, amount of exercise or self-reported health status. Patients who matched their top drug
recommendation using the multi-gene weighted algorithm differed significantly in height, weight, and
BMI compared to patients who did not match their top drug recommendation (Table 4).
Table 2. Percent of Patients on the Target Drug Classes as Determined by Genotype.
Gene Identifier HomozygousFunctional Heterozygous
Homozygous
Non-Functional
B-Blockade
Cyp2D6 *4 rs3892097 32 28 31
ADRB1
rs1801252 37 19 32
rs1801253 30 28 32
ADRB2
rs1042713 35 64 32
rs1042714 35 45 31
ACE-Inhibitor
ACE (I/D) rs1799752 52 42 49
AGT
rs699 56 31 46
rs5051 51 40 47
rs7079 52 17 48
AGTR1 rs5186 53 15 50
REN rs12750834 50 70 49
Angiotensin-II Receptor Blocker
ACE (I/D) rs1799752 24 72 22
AGT
rs699 22 60 25
rs5051 21 68 24
rs7079 17 44 23
AGTR1 rs5186 25 37 24
REN rs12750834 22 89 22
Diuretic
SCNN1A rs2228576 44 74 36
WNK1
rs1159744 39 26 38
rs2107614 42 77 39
rs2277869 41 94 38
SLC12A3 rs1529927 40 30 39
ADD1 rs4961 38 12 43
Data are represented as percent (%) on target therapy as described. ACE: angiotensin-converting enzyme.
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Table 3. Percent of Patients on the Target Drug Class as Determined by the Algorithm.
Study
Population
Match with
Recommendation #1
No Match with
Recommendation #1
Diuretic (%) 46.1 53.9 43.2
ACE-Inhibitors (%) 50.1 54.2 50.3
Angiotensin-II
Receptor Blockers (%) 24.5 12.2 25.8
B-Blockers (%) 24.6 64.2 11.6
Other (%) 14.1 13.7 13.2
ACE: angiotensin-converting enzyme.
Table 4. Subject Characteristics (N, percent or mean ± SEM).
Match with
Recommendation #1
No Match with
Recommendation #1
N 92 292
Age (years) 59.9 ± 1.1 61.2 ± 1.8
Height (cm) 166 ± 3 153 ± 4 *
Weight (kg) 94.6 ± 2.0 89.5 ± 1.1 *
BMI (kg/m2) 32.7 ± 0.8 30.8 ± 0.3 *
Past Smoker 43% 38%
Drinks (per week) 6.5 ± 0.8 5.7 ± 0.4
Exercise (min/week) 124 ± 28 193 ± 21
Self-Reported Health Status (0–4) 3.12 ± 0.06 3.16 ± 0.03
There was a statistically significant difference in height, weight, and body mass index (BMI) between patients whose
therapy matched their primary genetically recommended drug class compared to patients whose therapy did not.
* p < 0.05.
There was no difference in initial BP at diagnosis between groups matching the top drug
recommendation using the multi-gene weighted algorithm compared with those who did not match
their top drug recommendation. Further, there was no difference between groups in the percent of
patients under BP control as defined by Joint National Committee (JNC) and SPRINT guidelines
(Table 5). However, from diagnosis to nadir, patients who matched the primary recommendation had
a significantly greater drop in BP when compared to patients who did not (∆SBP = −39.2 ± 2.4
vs. −32.1 ± 1.3 mmHg, ∆DBP = −19.4 ± 1.1 vs. −14.0 ± 1.3 mmHg, ∆MAP = −24.4 ± 2.1
vs. −19.0 ± 1.2 mmHg, respectively, p < 0.05 for SBP and DBP). Further, the difference between
diagnosis to current 1-year average BP was lower in the group that matched the top recommendation
(∆SBP =−33.2± 2.3 vs. −27.4± 1.2 mmHg, ∆DBP =−14.8± 1.1 vs. −11.5± 1.2, ∆MAP = −21.2 ± 2.3
vs. −15.6 ± 1.8, respectively, p < 0.05 for SBP and MAP) (Figure 1).
In order to better assess the effect of the algorithm on drug response, we calculated the change
in BP and HTN control rates in a sub-group of patients on monotherapy (Table 6). In this group, if a
patient matched the primary drug recommendation, they tended to have a lower change in BP from
the time of diagnosis (~5 mmHg, on average), but this was not statistically significant. Interestingly,
patients who matched the first drug recommendation, and were only on one pharmacotherapy, were
~50% more likely to have their BP under control using the newer SPRINT guidelines (27% control vs.
18% control, for those patients who were on only one medication and matched the first algorithmic
recommendation compared to those who did not match, respectively).
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Table 5. Current BP Measures, Changes in BP, and BP Control Rates in Patients Who Match the Initial
Recommendation vs. Those Who Do Not (percent or mean ± SEM).
Match with
Recommendation #1
No Match with
Recommendation #1
Current SBP (mmHg) 128 ± 1 128 ± 1
Current DBP (mmHg) 79 ± 0 78 ± 1
Current MAP (mmHg) 95 ± 1 95 ± 1
Normotensive (JNC) 84% 85%
Normotensive (SPRINT) 27% 22%
SBP: systolic blood pressure, DBP: diastolic blood pressure, MAP: mean arterial blood pressure (calculated from
SBP and DBP). JNC: The Joint National Committee BP guidelines (<140/<90). SPRINT: Systolic Blood Pressure
Intervention Trial (<120/<80).
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Figure  1.  Change  in  Blood  Pressure  for  Patients  Whose  Therapy  Matched  the  Primary 
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Figure 1. Change in Blood Pressure for Patients Whose Therapy Matched the Primary Recommendation
Compared to Patients Whose Therapy did not. Panels depict the change in systolic blood pressure
(SBP), diastolic blood pressure (DBP), and mean arterial blood pressure (MAP) from diagnosis to the
lowest measurement and from diagnosis to current one-year average between patients whose therapy
matched the genetically determined primary drug class compared to patients whose therapy did not
match. * p < 0.05.
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Table 6. Current BP Measures, Change in BP, and BP Control Rates in Patients on Monotherapy
(N, percent or mean ± SEM).
Match with
Recommendation #1
No Match with
Recommendation #1
N 28 129
Current SBP (mmHg) 127 ± 1 128 ± 1
Current DBP (mmHg) 79 ± 0 79 ± 1
Current MAP (mmHg) 94 ± 1 96 ± 0
∆SBP (mmHg) −32.8 ± 3.5 −29.6 ± 2.8 *
∆DBP (mmHg) −14.5 ± 3.3 −11.8 ± 2.3 *
∆MAP (mmHg) −21.0 ± 2.5 −16.5 ± 2.3 *
Normotensive (JNC) 92% 85%
Normotensive (SPRINT) 27% 18%
* p < 0.05. There was a statistically significant difference in ∆SBP, ∆DBP, and ∆MAP for patients on monotherapy
whose therapy matched their primary genetically recommended drug class compared to patients whose therapy
did not. SBP: systolic blood pressure, DBP: diastolic blood pressure, MAP: mean arterial blood pressure (calculated
from SBP and DBP). JNC: The Joint National Committee BP guidelines (<140/<90). SPRINT: Systolic Blood Pressure
Intervention Trial (<120/<80).
Because many patients are on more than one pharmacotherapy, we also assessed the response
to treatment for patients who matched the drug recommendation one or drug recommendation two
from the algorithm. From this analysis, we found that there was no significant difference in the drop
in blood pressure between patients matching recommendation one or recommendation two, but that
patients who did match were slightly more likely to have their BP under control with the newer
SPRINT guidelines (27% vs. 22% for those matching recommendation one or two vs. those who did
not match, respectively) (Table 7).
Table 7. Current BP Measures, Changes in BP, and BP Control Rates in Patients Who Match Either
Recommendation #1 or Recommendation #2 (N, percent or mean ± SEM).
Match with
Recommendation #1 OR #2
No Match with
Recommendation #1 OR #2
N 136 218
Current SBP (mmHg) 128 ± 1 128 ± 1
Current DBP (mmHg) 79 ± 0 79 ± 1
Current MAP (mmHg) 94 ± 1 95 ± 0
Delta SBP (mmHg) −34.4 ± 1.7 −31.8 ± 2.3
Delta DBP (mmHg) −15.1 ± 1.2 −13.0 ± 2.2
Delta MAP (mmHg) −20.4 ± 1.3 −17.3 ± 2.1
Normotensive (JNC) 85% 84%
Normotensive (SPRINT) 27% 22%
SBP: systolic blood pressure, DBP: diastolic blood pressure, MAP: mean arterial blood pressure (calculated from
SBP and DBP). JNC: The Joint National Committee BP guidelines (<140/<90). SPRINT: Systolic Blood Pressure
Intervention Trial (<120/<80).
4. Discussion
In this study, we assessed the BP values and hypertension status between HTN patients who
matched the top drug recommendation using a multi-gene scientifically-weighted algorithm and
those who did not match. Our data suggest that few patients’ (24%) prescribed therapy matched
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their recommended therapy using the weighted algorithm. However, patients who matched the
primary recommendation had a significantly greater drop in BP (SBP, DBP, and MAP), from the time
of diagnosis to current clinical data, when compared to patients who did not match. Further, the
difference between diagnoses to the current one-year average BP was lower in the group that matched
the top recommendation. Additionally, for patients on monotherapy, those matching the primary
algorithmic drug recommendation were ~50% more likely to have their BP under control using the
newer SPRINT guidelines. Interestingly, subjects who matched the first drug recommendation were
heavier and tended to exercise less, suggesting the possibility that the findings are rather conservative.
Collectively, these data suggest that a multi-gene scientifically-weighted algorithm is more effective in
determining BP response and guiding HTN therapy than monogenic therapy alone.
Hypertension is a highly multi-factorial disease modulated by multiple susceptibility genes,
suggesting a large genetic determinant to HTN therapy response. Research examining genetic
determinants to HTN therapy response have identified β1-adrenergic receptor (ADRB1), β2-adrenergic
receptor (ADRB2), cytochrome P450 2D6 (CYP2D6), lysine deficient protein kinase (WNK),
sodium-chloride symporter (SLC12A3), alpha subunit of the epithelial sodium channel (SCNN1A),
alpha-adducin (ADD1), renin, angiotensin, angiotensin-converting enzyme (ACE), and angiotensin
receptor variants as playing functional roles in response to HTN therapy [12,16,24–26]. The influence
of multiple genes on HTN therapy response suggests that the multi-gene therapies, based on the
strength of previous peer-review studies, would be more effective than monogenic therapy.
A primary pathway responsible for the modulation of fluid balance and BP maintenance is the
renin-angiotensin-aldosterone system (RAAS). Within the RAAS, renin and angiotensin-converting
enzyme (ACE) are integral in the formation of angiotensin II (Ang II), the primary product of RAAS and
a potent vasoconstrictor [78]. Angiotensin II has several functions in the cardiovascular system, kidney,
sympathetic nervous system, and adrenal cortex important in BP maintenance [79]. The research
focused on genetic variations of the ACE-inhibitor (ACEI), Ang I, and the Ang II receptor suggests that
the renin-dependent mechanisms are involved in approximately 70% of HTN [78]. Specifically, the
deletion variant of ACE (rs7079), the C variant of Angiotensin (rs699), the C variant of the angiotensin-II
receptor (rs5186), and the C-5312T variant of REN (rs12750834) have shown improved response to
ACEI and Ang II receptor antagonism and decreased risk of stroke and coronary heart disease with
therapy [27–30,69].
Additional regulators of RAAS products, integral in BP homeostasis, are the beta-adrenergic
receptors (ADRB1, ADRB2). The beta-adrenergic receptors are found primarily in the heart and
juxtaglomerular cells of the kidney where they mediate important cardiovascular responses and
RAAS activity [80]. Stimulation of the beta-adrenergic receptors in the kidney induces renin release
activating RAAS [81,82]. Aldosterone, a downstream product of RAAS, preferentially increases renal
tubular luminal Na+ transport and plays a functional role in fluid volume and BP regulation [83].
Furthermore, SBP and DBP are impacted by RAAS activity and reflect Na+ retention [83]. The role
the beta-adrenergic receptors play in RAAS activation demonstrates the functional role they play in
HTN. Currently, BP response to beta-blockers has focused primarily on genetic variants of ADRB1
and ADRB2. Specifically, the Ser49 and Arg389 of ADRB1 (rs1801252 and rs1801253 respectively) and
the Arg16 and Glu27 of ADRB2 (rs1042713 and rs1042714 respectively) have demonstrated improved
responsiveness to and decreased adverse event risk and mortality with beta-blockade [31–33,37,38].
Additional mechanisms of action of aldosterone and Ang II is the modulation of Na+ reabsorption
and K+ secretion through direct epithelial sodium channel (ENaC) stimulation [79]. The epithelial
sodium channel (ENaC) is an ion channel critical in the maintenance of extracellular fluid volume,
BP, and sodium homeostasis via Na+ reabsorption and H2O diffusion across the apical membrane
of renal nephrons [84,85]. The research suggests that SCNN1A is the primary regulator of Na+ flux
through ENaC and genetic variations of SCNN1A are associated with BP modulation [86,87]. While
ENaC regulates Na+ transport across the luminal plasma membrane, Na-K-ATPase regulates Na+
transport across the basolateral plasma membrane. This suggests that the complex interplay between
J. Clin. Med. 2019, 8, 289 11 of 17
the Na-K-ATPase and ENaC is an important pathway in fluid volume regulation [34]. The primary
regulator of this complex is adducing, which is responsible for the expression and maximum velocity
of Na-K−ATPase and subsequently increases renal tubular Na+ reabsorption [88–90]. The research has
demonstrated genetic variants of the alpha-adducin subunit (ADD1) influencing HTN development
risk and diuretic therapy responsiveness [34]. Specifically, the T variant of alpha-adducin (rs4961) has
been shown to be more responsive to a diuretic and to halve the risk of myocardial infarction and
stroke with BP control [34,40].
Other pathways in fluid volume and BP regulation include ion co-transporters that modulate Na+
reabsorption in the kidneys, including members of the SLC12 family of ion transporters and have vital
roles in regulating electrolyte transport and BP [91]. These transporters are targets for thiazide-diuretic
and loop-diuretic therapy for BP control. The SCL12A is a kidney-specific isoform expressed in
the distal convoluted tubule, and the C variant of SLC12A3 (rs1529927) has been demonstrated
to be more responsive to diuretic therapy [34,91]. Furthermore, the research has identified lysine
deficient protein kinases (WNKs) as upstream regulators of these pathways [36]. The research has
demonstrated that WNK1 (the kidney-specific isoform) plays a regulatory role in electrolyte transport
across renal membranes and epithelia, suggesting a functional role in BP maintenance [35,92,93].
Further, genetic variations of WNK1 have been associated with an ~5–6 mmHg variability in BP
response to hydrochlorothiazide (rs2107614, rs1159744, and rs2277869) [12,35,36]. This relationship is
likely attributable to the improved Na+ and Cl− excretion associated with these variants [41].
To further understand the influence of pharmacotherapy on BP response, it is necessary to consider
pharmacokinetics. The liver is the principal site of drug metabolism, primarily by a class of proteins
called Cytochrome P450 (CYP). To date, 12 human CYPs have been identified, including CYP2D6 [94].
While CYP2D6 only accounts for 2–8% of all hepatic CYPs, it is responsible for the metabolism of
approximately 25% of clinically used drugs [94,95]. Two common variants of the CYP2D6 have been
identified as either fully functional (CYP2D6*1) or non-functional (CYP2D6*4). These genetic variations
of CYP2D6 have been associated with responsive beta-blocker therapy through differential metabolism.
The research has demonstrated CYP2D6*4 carriers to have an up to 5-fold increase in plasma drug
levels after beta-blocker therapy [25]. Despite this dramatic difference in plasma beta-blocker levels,
most studies have demonstrated no effect on BP as an outcome variable.
Cumulatively, these data suggest that HTN is a complex, multi-factorial disease comprised of
multiple organ systems and pathways. While there is a push towards a “personalized medicine”
approach to BP pharmacotherapy, the current clinical treatment strategy is based on a set algorithm
which bases its recommendations on drug class and does not differentiate between drug classes [96].
As a result, different clinical algorithms preferentially recommend certain drug classes over others [96].
Furthermore, commonly used algorithms categorize their patients by age, ethnicity, hypertensive
stage, and other clinical characteristics (i.e., diabetes, coronary disease, etc.) to guide HTN
patient pharmacotherapy [96]. To date, clinical algorithms fail to fully incorporate genetics-based
pharmacotherapy for BP control.
The influence of the aforementioned genetic variants on BP response to therapy clearly
demonstrates the impetus for a multi-gene approach to pharmacotherapy. This study has been
built on previous monogenic studies with the inclusion of multiple genotypes in multiple organ
systems, and on previous multi-gene studies with the implementation of a weighted, multi-gene
algorithm for determining BP response to therapy. The current study demonstrated a significantly
greater drop in BP in patients who matched the primary recommendation when compared to patients
who did not. Further, the difference between diagnoses to current 1-year average BP was lower in
the group that matched the top recommendation. These data suggest an algorithm that is weighted
based on the strength of previous peer-review studies, is multi-gene in nature and predictive of the BP
response to pharmacotherapy compared to the current standard of care, however, prospective trials
are needed.
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5. Conclusions
The purpose of this study was to assess seventeen common genetic variants in the liver (drug
metabolizing enzyme), cardiac, vascular, and renal systems to determine the effectiveness of a weighted
multi-gene algorithm on predicting BP response to therapy. We demonstrated an association between
a scientifically-weighted multi-gene algorithm and the BP response to pharmacotherapy. From a
patient-centric outcomes perspective, this magnitude of the difference is associated with a significant
reduction in heart attack and stroke risk. These findings can be applied to improving therapeutic
guidance for clinicians based on known functional alterations of the protein through these genetic
changes. Based on these findings, clinicians can guide therapy with knowledge specific to their patient,
rather than “trial-and-error” based on population data, which will improve therapy efficacy and reduce
healthcare costs, adverse events, and time to control BP. Given the retrospective nature of this trial,
future randomized trials, which are controlled for the standard of care, are needed.
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